
News and Publications
Publication Categories
LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade
Explore how LFA-1 activation with 7HP349 enhances T cell infiltration in cold tumors and synergizes with CTLA-4 blockade for improved cancer immunotherapy. Learn more about its impact on tumor immunity.
Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease
Discover how 7HP349, a novel integrin activator, enhances vaccine efficacy by boosting T cell-mediated immune responses. Learn how this systemic adjuvant improves protection against Chagas disease and other infections.
Immune activators – enhancing cell adhesion to safely improve effectiveness of vaccines & cancer immunotherapies
7 Hills Pharma develops integrin activators like 7HP349 to enhance vaccine efficacy and immunotherapy for cancer. Learn how their breakthrough technology boosts immune response in vulnerable populations.
Integrin-mediated augmentation of antigenic immunity
Explore how 7HP349, a novel integrin activator, enhances immune responses in cancer therapy and vaccine efficacy. Learn about its role in boosting T cell activation, checkpoint blockade, and pathogen-specific immunity with a strong safety profile.
Potentiating immune checkpoint blockade therapeutic efficacy using a small molecule activator of integrin cell adhesion receptors
Discover how the small molecule integrin activator 7HP349 enhances immune checkpoint blockade therapy by promoting T cell infiltration into tumors. Learn about its role in boosting anti-CTLA-4 and anti-PD-L1 efficacy in melanoma and colon cancer models.
Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment
Explore the complex relationship between the immune system and cancer, focusing on integrins and cell adhesion molecules in tumor development, immune responses, and cancer immunotherapy strategies.
Cancer vaccines: trafficking of tumor-specific T cells to tumor after therapeutic vaccination
Discover how cancer vaccines enhance tumor-specific CD8+ T cell trafficking, activation, and infiltration for effective tumor regression. Learn about next-generation immunotherapy strategies to improve cancer vaccine efficacy.
T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy
Discover how tumors evade immune responses and limit cancer immunotherapy success. Explore strategies to enhance T-cell and NK-cell infiltration, overcome tumor immune barriers, and improve treatment efficacy.
Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion
Discover THI0019, the first small molecule agonist of VLA-4 integrin, designed to enhance progenitor cell adhesion and improve stem cell therapy outcomes. Learn how integrin activation can boost cell retention, migration, and engraftment.
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Explore the link between angiogenesis and immunosuppression in cancer. Learn how tumors exploit these processes and discover emerging cancer therapies targeting both vascular growth and immune evasion.
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes
Discover how agonist anti-CD137 monoclonal antibodies enhance T cell recruitment by acting on tumor endothelial cells. Learn about their role in cancer immunotherapy and potential for improving immune infiltration in tumors.
The importance of prolonged binding to antigen-presenting cells for T cell fate decisions
Discover the crucial role of prolonged T cell interactions with antigen-presenting cells (APCs) in immune response regulation. Learn how ICAM-1 and LFA-1 signaling influence T cell activation, memory formation, and immune system efficiency.
Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory
Discover how ICAM-1 expression on dendritic cells regulates CD8+ T cell priming, immune memory formation, and cytotoxic T lymphocyte activation. Learn about the role of long-lasting DC-T cell interactions in effective immune responses.
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
Explore how the Endothelin B receptor (ETBR) inhibits T cell homing, limiting tumor immunotherapy efficacy. Learn about ICAM-1’s role in immune cell infiltration and how ETBR blockade can enhance cancer treatment outcomes.
Tumor blood vessels, a difficult hurdle for infiltrating leukocytes
Explore how tumors evade immune responses by suppressing endothelial adhesion molecules, limiting leukocyte recruitment. Learn about novel strategies to enhance immune cell infiltration and improve cancer immunotherapy outcomes.
Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma
Explore how Vascular Adhesion Protein-1 (VAP-1) and ICAM-1 facilitate T cell adhesion to tumor endothelium in hepatocellular carcinoma (HCC). Learn about their role in tumor immune infiltration and potential implications for cancer immunotherapy.
Regulation of human T lymphocyte coactivation with an alpha4 integrin antagonist peptide
Discover how the cyclic hexapeptide CWLDVC (TBC 772) acts as an alpha4 integrin antagonist, effectively inhibiting human T lymphocyte coactivation and immune cell adhesion. Learn about its potential in targeted immune therapies.
Alpha 4 beta 1 (CD49d/CD29) integrin costimulation of human T cells enhances transcription factor and cytokine induction in the absence of altered sensitivity to anti-CD3 stimulation
Explore how Alpha 4 Beta 1 (CD49d/CD29) integrin enhances T cell costimulation, driving cytokine induction and transcription factor activation. Learn about its role in immune cell signaling and response modulation.
Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors
Discover how angiogenic factors suppress ICAM-1 expression in tumors, limiting leukocyte infiltration and aiding immune evasion. Learn about the role of endothelial adhesion molecules in cancer progression and potential therapeutic strategies.